Research

Are Peptides Safe? What the Risk Depends On

Creator: Nadia Okonjo, Health Writer
Published: 2026-08-24

Safety is not a property a molecule carries on its own. It belongs to the compound plus a dose, plus the vial it came from, plus the person injecting it, plus someone qualified who is accountable for the decision.

Nadia Okonjo, Health Writer August 24, 2026 7 min read

Two adults in fitted long-sleeve tops sit talking across a small table by a window in warm afternoon light

The short version

"Safe" is not a property of a peptide. It belongs to the compound plus the dose, the source of the vial, the medical history of the person injecting it, and whether a clinician is accountable for the decision.
Most compounds in this category are not FDA-approved and the human evidence is thinner than for approved drugs — BPC-157 has a large body of animal work and no published randomised controlled trial in humans as of August 2026. A licensed provider may still prescribe a compounded formulation where they judge it appropriate.
The biggest product risk is identity rather than side effects: doping-control laboratories analysing seized growth-promoting products found a modified growth hormone and three growth-hormone-releasing peptides each carrying an extra amino acid — different molecules from the ones on the labels.
Dose error is the commonest everyday harm. The FDA's July 2024 alert on compounded injectable semaglutide described hospitalisations after people confused millilitres, milligrams and "units" and measured several times the amount intended.
Unscreened use produces the published harms: one case report describes rhabdomyolysis with creatine kinase peaking at 17,773 IU/L after a 6 mg internet-bought melanotan II injection, six times the starting amount the seller suggested.
A 503A compounding pharmacy is licensed, inspected and recallable and works to United States Pharmacopeia sterile standards — the framework written after contaminated methylprednisolone from one pharmacy caused 749 fungal infections and 61 deaths.

"Are peptides safe?" is not a question a molecule can answer by itself. Safety here is a property of a compound plus a dose, plus the vial it actually came from, plus the medical history of the person injecting it, plus whether a qualified clinician is accountable for the decision. Change any one of those four and the answer changes.

Two of the four are settled by how you obtain the compound rather than by pharmacology. A prescribed peptide arrives from a state-licensed compounding pharmacy on a written prescription, after a clinician has read your history. The same molecule from an anonymous seller arrives with none of that, and most of the documented harm here traces back to that difference rather than to the peptide.

Are peptides safe? Four variables decide it

Variable	What goes wrong when nobody manages it
The dose	Overdose from a miscalculated draw, or confusion between millilitres, milligrams and "units".
The source	Wrong molecule, wrong quantity, degraded material, bacterial or endotoxin contamination.
The person	A contraindication nobody screened for — cancer history, interacting medication, pregnancy.
Accountability	Nobody to report a reaction to, nobody to adjust the dose, no recall route.

Only the first row is about pharmacology. The other three are about process, and process is the part you can choose.

What the human evidence actually shows

The evidence base for therapeutic peptides is thinner than for approved drugs, and pretending otherwise would be the least safe thing on this page. BPC-157 is the clearest case: a large body of animal work and, as of August 2026, no published randomised controlled trial in humans for any indication. A 2026 review in Cureus (Hailu et al., Cureus 2026) sets out why that gap matters: uncertain product identity, variable purity, inaccurate potency, contamination and weak adverse-event surveillance compound one another, none of it visible to the person holding the vial.

Regulators have not closed the question either. The FDA placed BPC-157 among the bulk substances that may present significant safety risks in September 2023, and at the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 the committee voted to recommend it, KPV and TB-500 for the 503A list. Those votes are advisory and rulemaking has not concluded.

Most compounds in this category are not FDA-approved, and the compounded preparations of them are not FDA-approved either. That is a statement about a regulatory file rather than a verdict on the person in front of the clinician: a licensed provider may still prescribe a compounded formulation where they judge it appropriate, and that decision is between you and your doctor.

Peptide therapy risks that start in the vial

The most under-appreciated risk here is not a side effect. It is that the vial does not contain what the label says.

Doping-control laboratories in Cologne and Oslo analysed seized growth-promoting products and found a growth hormone carrying an extra alanine, plus three growth-hormone-releasing peptides — GHRP-6, GHRP-2 and ipamorelin — each carrying an extra glycine (Krug et al., Growth Horm IGF Res 2018). Those were not impurities but different molecules from the ones on the packaging, with no human data of their own.

Vials sold outside a prescription route are typically labelled for laboratory use and not sold for human use. That label is the seller stating that nothing about the contents has been prepared, tested or documented for a person, and a certificate of analysis does not close the gap: as the Cureus review puts it, such a certificate may say nothing reliable about sterility, endotoxin burden, degradation or batch consistency. Whether peptides can be bought over the counter at all is a separate question.

The risks that come from having no supervision

Dose is the everyday one. In July 2024 the FDA alerted providers and patients to dosing errors with compounded injectable semaglutide, including adverse events serious enough to require hospitalisation: people unfamiliar with drawing from a vial confused millilitres, milligrams and "units" and measured several times the amount intended. That is an arithmetic failure, not a pharmacological one, which is why how a peptide is reconstituted and measured is worth understanding first.

Screening is the other one. A man developed sympathomimetic toxicity, rhabdomyolysis and renal dysfunction after injecting 6 mg of melanotan II bought over the internet — six times the starting amount the seller suggested — with creatine kinase peaking at 17,773 IU/L (Clinical Toxicology, 2012). A dermatology case report links a self-injected course of the same compound, alongside sunbed use, to a melanoma excised three months later (Dermatology, 2014) — an observation, not proof of cause. A prescriber asks about skin-cancer history before a melanocortin compound is considered. A seller asks for a card number.

What a prescriber actually screens for

Growth-hormone-releasing peptides make the point plainly. Sermorelin and tesamorelin are GHRH analogues, and they move real physiology rather than nudging it: in a 26-week randomised trial of 412 patients, tesamorelin raised IGF-I by 81.0% while the placebo group fell 5.0%, and though adverse events did not differ significantly between groups, more patients on tesamorelin withdrew because of one (Falutz et al., NEJM 2007). A compound that shifts a growth-signalling hormone that far needs someone reviewing a cancer history, a glucose result and an IGF-1 level.

That is the shape of the screen: your history against the compound's mechanism, current medications for interactions, pregnancy or breastfeeding, whether the request is medically coherent, and whether the provider holds a licence where you live. Getting a peptide prescribed walks it end to end.

A licensed provider in Promise's prescriber network reviews every request and prescribes only where it is appropriate for the person asking. Not everyone qualifies, and a decline is information rather than an obstacle.

Side effects of peptides: what is common and what is unknown

Injection-site reactions — redness, itching, a small firm lump — are the most commonly reported effect across the injectable compounds here, and are usually mild and short-lived. Past that the profile is compound-specific: GLP-1 medicines are dominated by nausea, GHRH analogues by flushing, headache and fluid retention.

Route matters as much as molecule. NAD+ is given as a slow infusion or a subcutaneous injection because speed drives the unpleasant part, and the only published human work on directly infused NAD+ is a pilot study of a six-hour intravenous infusion (Grant et al., Front Aging Neurosci 2019). The better-characterised tolerability data belong to an oral precursor taken by a different route (Martens et al., Nat Commun 2018) — a distinction a seller's summary tends to lose.

Treat "no reported side effects" on a product page as what it usually is: nobody was collecting reports.

What a licensed compounding pharmacy is held to

Compounding under section 503A means a state-licensed pharmacy preparing a medication for an identified patient against a prescription. Those preparations are exempt from FDA pre-market review, and in exchange are bound by state pharmacy law and by United States Pharmacopeia standards for sterile compounding — controlled air environments, beyond-use dating, sterility and endotoxin testing.

A compounded preparation is not a generic and not a brand: it has not been through FDA approval, and the agency does not review it for safety, effectiveness or quality. What it does have is an address. The pharmacy is licensed, it is inspected, and it can be made to recall a batch.

That machinery exists because of what happens without it: contaminated methylprednisolone from one compounding pharmacy caused 749 fungal infections across 20 states and 61 deaths (Smith et al., NEJM 2013), and the federal compounding framework in force today was written in the aftermath. How compounded medications are actually made covers the process.

Where that leaves the question

The compounds sit on an uneven evidence base, and that is worth saying plainly. What you can choose is everything around them: a molecule identified and tested, a dose someone qualified set, a history someone read, and a name to call when something feels wrong. None of that is in the vial.

Common questions

Are peptides safe?

It depends on four things rather than on the molecule alone: the dose, the source of the vial, the medical history of the person taking it, and whether a qualified clinician is accountable for the decision. A peptide prescribed after a medical review and dispensed by a licensed compounding pharmacy carries a very different risk profile from the same molecule bought anonymously online.

Are peptides FDA-approved?

No. A few of these molecules have FDA-approved brand products — semaglutide and tirzepatide among them — but the compounded formulations dispensed here are not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality. That is a regulatory fact rather than a prescribing verdict: a licensed provider may still prescribe a compounded formulation where they judge it appropriate.

What are the main risks of peptide therapy?

They cluster into four groups: product risks (wrong molecule, wrong quantity, degraded material, bacterial or endotoxin contamination), dosing errors, unscreened contraindications such as a cancer history or an interacting medication, and having nobody to report a reaction to. Only the first group is chemistry. The rest follow from an unsupervised supply route rather than from the peptide.

Are peptides bought online the same as prescribed ones?

No — the difference is what can be verified. A prescribed peptide is prepared for an identified patient by a state-licensed compounding pharmacy that is inspected and can be made to recall a batch. Vials sold outside a prescription route are typically labelled for laboratory use and not sold for human use, and a certificate of analysis says little about sterility, endotoxin burden or storage.

What are the most common side effects of peptides?

Injection-site reactions — redness, itching, a small firm lump — are the most commonly reported effect across the injectable compounds in this category, and are usually mild and short-lived. Beyond that it is compound-specific: GLP-1 medicines are dominated by nausea and other gastrointestinal effects, GHRH analogues by flushing, headache and fluid retention. A page claiming no reported side effects usually means nobody was collecting reports.

Who should not use peptide therapy?

A provider will generally decline anyone pregnant or breastfeeding, and screens carefully for an active or recent cancer diagnosis, a personal or family history relevant to the compound's mechanism, interacting medications, and untreated conditions the compound could worsen. They must also hold a licence in your state. Being declined is a real outcome, and the reason is worth asking for.